The largest database of trusted experimental protocols

Pcdna3 backbone

Manufactured by Thermo Fisher Scientific

The PcDNA3 backbone is a DNA plasmid vector commonly used in molecular biology and genetic engineering. It serves as a base for the construction of recombinant DNA molecules and enables the expression of genes or proteins of interest in various cell lines.

Automatically generated - may contain errors

3 protocols using pcdna3 backbone

1

Optogenetic Luciferase Fusion Constructs

Check if the same lab product or an alternative is used in the 5 most similar protocols
All constructs were initially cloned into the pcDNA3 backbone (Invitrogen) for ease of comparison. The luciferase constructs (TagRFP-Rluc8.638 (link) was a gift from Dr. Sanjiv Gambhir; Firefly luciferase15 (link) was a gift from Dr. Phil Sharp, Addgene plasmid #11510; Nano-lantern14 (link) was a gift from Dr. Takeharu Nagai, Addgene plasmid # 51970) were all PCR amplified and cloned into the pcDNA3 vector for direct comparison of expression and bioluminescence. The NpHR coding sequence was PCR amplified from the pAAV-eNpHR3.0-EYFP plasmid (gift from Dr. Karl Deisseroth) and inserted into the PCDNA3 vector. The EYFP coding sequence was digested out of this plasmid using EcoRI/NotI restriction sites to leave a backbone containing NpHR. iLMO1 was created by PCR amplifying out the TagRFP-Rluc8.6 cassette and inserting it in-frame downstream of NpHR. iLMO2 was created in a similar fashion, where the Nano-lantern cassette was PCR amplified (Forward primer: 5′ ATCGGAATTCGTGAGCAAGGGCGA, Reverse primer: 5′ ATCGCTCGAGTTACACCTCGTTCTCGTAGCAGAACTGCTCGTTCTTCAGCAC) and cloned downstream of the NpHR coding sequence. Both constructs also included an ER-export sequence39 (link) at the 3′ end of the fusion protein. The iLMO1 and iLMO2 cassettes were subsequently cloned into the FUGW lentiviral backbone and the pAAV backbone for production of 2nd generation lentivirus and AAV2/9, respectively.
+ Open protocol
+ Expand
2

Molecular Mechanisms of Cell-Cell Adhesion

Check if the same lab product or an alternative is used in the 5 most similar protocols
ON-TARGETplus SMARTpool small interfering RNAs (siRNAs) were purchased from Dharmacon: ID1 (#L-005051-00-0005), ID3 (#L-009905-00-0005), ROCK1 (#L-003536-00-0005), p120 (#L-012572-00-0005), YAP (#L-012200-00-0005), non-targeting control (#D-001810-10-50). Cells were reverse-transfected with 1 pmol/10 nM of each siRNA in 96-well plates using Lipofectamine RNAiMAX (Life Technologies) and Opti-MEM (Thermo Fisher Scientific) following manufacturer’s instructions. pCDNA3 backbone was from Invitrogen and hE-cadherin-pcDNA3 was a gift from Barry Gumbiner (Addgene plasmid # 45769). Plasmids were forward transfected into cells using FuGENE 6 (Promega). BEZ-235, LY-294002, GSK-1120212, SCH-772984 and LJH-685 were purchased from Selleck Chemicals. Y-27632 was purchased from Sigma Aldrich.
+ Open protocol
+ Expand
3

In vivo Expression of FVIII Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 2

Expression plasmids containing the various FVIII variants were designed for in vivo expression. The non-optimized BDD FVIII (FIG. 1I; SEQ ID NO: 16) and coFVIII-1 (FIG. 11Z; SEQ ID NO: 68) polynucleotides were cloned into a pcDNA3 backbone (Invitrogen), wherein the CMV promoter was replaced by an ET promoter (see FIG. 3). The resulting plasmids, FVIII-311 (BDD FVIII) and FVII-303 (coFVIII-1), drive the expression of non-optimized BDD FVIII and coFVIII-1, respectively.

In vivo expression of FVIII-311 and FVII-303 was evaluated in Hem A mice by hydrodynamic injection of 5 μg DNA/mouse of FVII-303 or FVIII-311. Plasma samples were collected at 24, 48, and 72 hours post-injection, and FVIII activity was determined by a FVIII specific chromogenic assay.

As shown in FIG. 4, the plasma FVIII activity of mice treated with FVII-311 (BDD FVIII; squares) was 74±43 mU/mL at 72 hours post-injection, whereas the plasma FVIII activity of mice treated with FVII-303 (coFVIII-1; circles) was 452±170 mU/mL at 72 hours post-injection (FIG. 4). This represents an approximately six-fold increase in the expression of coFVIII-1 relative to non-optimized BDD FVIII.

+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!